scholarly journals Clinical Experience of Auditory Brainstem Response Testing on Pediatric Patients in the Operating Room

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Guangwei Zhou ◽  
Briana Dornan ◽  
Wheaton Hinchion
Keyword(s):  
Hearing Loss ◽  
Operating Room ◽  
Auditory Brainstem Response ◽  
Tertiary Care ◽  
Care Facility ◽  
Auditory Brainstem ◽  
Medical Issues ◽  
Tertiary Care Facility ◽  
Brainstem Response ◽  
Response Testing

Objectives. To review our experience of conducting auditory brainstem response (ABR) test on children in the operating room and discuss the benefits versus limitations of this practice.Methods. Retrospective review study conducted in a pediatric tertiary care facility. A total of 267 patients identified with usable data, including ABR results, medical and surgical notes, and follow-up evaluation.Results. Hearing status successfully determined in all patients based on the ABR results form the operating room. The degrees and the types of hearing loss also documented in most of the cases. In addition, multiple factors that may affect the outcomes of ABR in the operating room identified.Conclusions. Hearing loss in children with complicated medical issues can be accurately evaluated via ABR testing in the operating room. Efforts should be made to eliminate adverse factors to ABR recording, and caution should be taken when interpreting ABR results from the operating room.

Universal Neonatal Hearing Screening: An Experience at Tertiary Care Hospital

2020 ◽  
Vol 18 (2) ◽  
pp. 57-61
Author(s):  
B.L. Shrestha ◽  
S. Karmacharya ◽  
A. Dhakal ◽  
A.K. KC ◽  
K.S. Shrestha ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Auditory Brainstem Response ◽  
Negative Impact ◽  
Tertiary Care ◽  
Auditory Brainstem ◽  
Hearing Screening ◽  
University Hospital ◽  
Care Hospital ◽  
Automated Auditory Brainstem Response ◽  
Brainstem Response

Background Hearing loss among neonates is one of the important health issue in pediatric population which may remain unnoticed until the child reaches a certain age. The importance of universal early screening, diagnosis and intervention in reducing the negative impact of congenital hearing loss has been described all over the world. Objective To observe the outcome of hearing screening by Automated Auditory Brainstem Response (AABR) in newborns delivered in Dhulikhel Hospital and neonates admitted in an intensive care unit (NICU) of Dhulikhel Hospital. Method A prospective study was done in neonates who were born at Dhulikhel Hospital, Kathmandu University Hospital from February 15th, 2017 to October 30th, 2019. AABR was used for their hearing assessment within 24 hours of birth and again at about 6 weeks of age in those neonates who failed the initial test. All the neonates admitted in NICU were studied regarding the risk factors based on Joint committee on Infant Hearing. Those who failed the test for the second time were referred for detailed audiological diagnostic work up. Result The screening rate was 92.6% of the total deliveries. A total of 5517 neonates comprising of 2800 males and 2717 females were screened from total deliveries of 5956 neonates in the study period. Among them, NICU (sick) babies were 422 (7.7%) and well babies were 5095 (92.3%). Out of them, 1675 failed the test in the first screening and 374 failed in the second screening. So, the total number of referred babies in second screening was 6.7% (374) out of 5517 screened. Amongst them, well babies were 6.59% (336), out of 5095 screened and sick babies were 9% (38) out of 422 screened. Low birth weight and prematurity were found to be the commonest risk factor present among them, followed by the use of ototoxic medications, hyperbilirubinemia and prolonged use of mechanical ventilation. Conclusion Automated Auditory Brainstem Response (AABR) is a very useful tool for hearing screening which should preferably be done in all the neonates where possible. It should be done within one month of life and those with confirmed hearing loss should receive early appropriate intervention for better hearing in future.

Comparison of 1000-Hz Toneburst and Click Stimuli in Otoneurologic ABR

1995 ◽  
Vol 4 (2) ◽  
pp. 55-60 ◽  
Author(s):  
Kathleen C. M. Campbell ◽  
Barbara A. Brady
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sensitivity And Specificity ◽  
Auditory Brainstem Response ◽  
Auditory Brainstem ◽  
Clinical Interpretation ◽  
Eighth Nerve ◽  
Latency Difference ◽  
Brainstem Response ◽  
Response Testing

The present study compares the utility of click and 1000-Hz toneburst stimuli in otoneurologic auditory brainstem response testing in 45 patients with cochlear sensorineural hearing loss and in 13 patients with tumors affecting the eighth nerve. Waves I and III occurred more frequently for the click stimulus than for the 1000-Hz stimulus in ears without tumors. In ears with tumors, Waves I and III were generally absent for both stimuli. Wave V was generally present in response to both stimuli. The Wave V interaural latency difference (ILD V) was significantly different between groups for both stimuli but was not significantly different between stimuli. The sensitivity and specificity were similar for the two stimuli. In selected cases and as an adjuvant measure, the additional use of the 1000-Hz toneburst was useful. Recommendations for clinical interpretation and application are discussed.

Efficiency of Stenger test in confirming profound, unilateral pseudohypacusis

2009 ◽  
Vol 123 (8) ◽  
pp. 840-844 ◽  
Author(s):  
A Durmaz ◽  
S Karahatay ◽  
B Satar ◽  
H Birkent ◽  
Y Hidir
Keyword(s):  
Hearing Loss ◽  
Auditory Brainstem Response ◽  
Gold Standard ◽  
Pure Tone Audiometry ◽  
Auditory Brainstem ◽  
Profound Hearing Loss ◽  
Predictive Values ◽  
Brainstem Response ◽  
Sensitivity Specificity ◽  
Response Testing

AbstractObjective:Conscious and deceptive exaggeration of hearing loss is termed pseudohypacusis. Even though the Stenger test has been used in the management of pseudohypacusis for almost a century, its sensitivity, specificity and predictive values for unilateral pseudohypacusis have not previously been reported, to our best knowledge. We investigated the efficiency of the Stenger test in detecting unilateral pseudohypacusis, accepting auditory brainstem response testing as the ‘gold standard’.Materials and methods:Candidates with questionable profound or total hearing loss were enrolled in the study. Pure tone audiometry, speech and tonal Stenger tests, and click test auditory brainstem response measurement were performed. Accepting auditory brainstem response testing as the gold standard, the sensitivity, specificity and predictive values of the Stenger test for unilateral, profound pseudohypacusis were assessed.Results:Two hundred military candidates were enrolled in the study. The sensitivity and specificity of the Stenger test in verifying unilateral, profound hearing loss were 99.4 and 70 per cent, respectively. The positive and negative predictive values of the test were 87.5 and 98.4 per cent, respectively.Conclusion:The Stenger test is widely used for the evaluation of unilateral or asymmetrical pseudohypacusis. In our opinion, it is a powerfully reliable test. More difficult cases require objective electrophysiological testing to verify functional hearing loss and to exclude specific diagnoses that may imitate pseudohypacusis.

scholarly journals Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Xi Gu ◽  
Daqi Wang ◽  
Zhijiao Xu ◽  
Jinghan Wang ◽  
Luo Guo ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Protective Effect ◽  
Hair Cell ◽  
Sensorineural Hearing Loss ◽  
Auditory Brainstem Response ◽  
Gene Editing ◽  
Auditory Brainstem ◽  
Sensorineural Hearing ◽  
Brainstem Response

Abstract Background Aging, noise, infection, and ototoxic drugs are the major causes of human acquired sensorineural hearing loss, but treatment options are limited. CRISPR/Cas9 technology has tremendous potential to become a new therapeutic modality for acquired non-inherited sensorineural hearing loss. Here, we develop CRISPR/Cas9 strategies to prevent aminoglycoside-induced deafness, a common type of acquired non-inherited sensorineural hearing loss, via disrupting the Htra2 gene in the inner ear which is involved in apoptosis but has not been investigated in cochlear hair cell protection. Results The results indicate that adeno-associated virus (AAV)-mediated delivery of CRISPR/SpCas9 system ameliorates neomycin-induced apoptosis, promotes hair cell survival, and significantly improves hearing function in neomycin-treated mice. The protective effect of the AAV–CRISPR/Cas9 system in vivo is sustained up to 8 weeks after neomycin exposure. For more efficient delivery of the whole CRISPR/Cas9 system, we also explore the AAV–CRISPR/SaCas9 system to prevent neomycin-induced deafness. The in vivo editing efficiency of the SaCas9 system is 1.73% on average. We observed significant improvement in auditory brainstem response thresholds in the injected ears compared with the non-injected ears. At 4 weeks after neomycin exposure, the protective effect of the AAV–CRISPR/SaCas9 system is still obvious, with the improvement in auditory brainstem response threshold up to 50 dB at 8 kHz. Conclusions These findings demonstrate the safe and effective prevention of aminoglycoside-induced deafness via Htra2 gene editing and support further development of the CRISPR/Cas9 technology in the treatment of non-inherited hearing loss as well as other non-inherited diseases.

Sign in / Sign up

Export Citation Format

Share Document